The expected toxicity rate at the maximum tolerated dose in bridging studies in Alzheimer's disease

Seung Ho Kang, Chul Ahn

Research output: Contribution to journalArticle

Abstract

A bridging study has been recommended to determine the maximum tolerated dose in Alzheimer's disease patients, because the maximum tolerated dose in the Alzheimer's disease patient population versus the normal population can vary greatly. Although bridging studies in Alzheimer's disease have often been conducted, it is surprising to note that very little is known about the statistical properties of the studies. For example, even how toxic the maximum tolerated dose is has not been examined. In addition, both the number of patients needed and the number of patients who will experience the toxicity cannot be predicted either. In this paper, we examine the exact statistical properties of a fixed-dose panel design which is frequently used in bridging studies in Alzheimer's disease. We introduce the formulas for the overall toxicity rate at the maximum tolerated dose, the expected number of patients who will experience the overall toxicity, and the expected number of patients in the bridging studies in Alzheimer's disease. The exact statistical properties of bridging studies depend on the unknown dose-toxicity curve. In this paper, we assume the logistic and the hyperbolic tangent functions as the true dose-toxicity curves, because the two families of functions seem to include most practical dose-toxicity curves. Based on the assumptions we investigate extensively the exact statistical properties of the bridging studies in Alzheimer clinical trials. The investigation shows that the expected toxicity rate at the maximum tolerated dose ranges from 18% to 30%. All rights reserved.

Original languageEnglish
Pages (from-to)149-157
Number of pages9
JournalDrug Information Journal
Volume39
Issue number2
DOIs
Publication statusPublished - 2005 Jan 1

Fingerprint

Maximum Tolerated Dose
Toxicity
Alzheimer Disease
Hyperbolic functions
Poisons
Population
Logistics
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology (nursing)
  • Drug guides
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

@article{df52a81088f44528ab5ac77a2c3e9b6f,
title = "The expected toxicity rate at the maximum tolerated dose in bridging studies in Alzheimer's disease",
abstract = "A bridging study has been recommended to determine the maximum tolerated dose in Alzheimer's disease patients, because the maximum tolerated dose in the Alzheimer's disease patient population versus the normal population can vary greatly. Although bridging studies in Alzheimer's disease have often been conducted, it is surprising to note that very little is known about the statistical properties of the studies. For example, even how toxic the maximum tolerated dose is has not been examined. In addition, both the number of patients needed and the number of patients who will experience the toxicity cannot be predicted either. In this paper, we examine the exact statistical properties of a fixed-dose panel design which is frequently used in bridging studies in Alzheimer's disease. We introduce the formulas for the overall toxicity rate at the maximum tolerated dose, the expected number of patients who will experience the overall toxicity, and the expected number of patients in the bridging studies in Alzheimer's disease. The exact statistical properties of bridging studies depend on the unknown dose-toxicity curve. In this paper, we assume the logistic and the hyperbolic tangent functions as the true dose-toxicity curves, because the two families of functions seem to include most practical dose-toxicity curves. Based on the assumptions we investigate extensively the exact statistical properties of the bridging studies in Alzheimer clinical trials. The investigation shows that the expected toxicity rate at the maximum tolerated dose ranges from 18{\%} to 30{\%}. All rights reserved.",
author = "Kang, {Seung Ho} and Chul Ahn",
year = "2005",
month = "1",
day = "1",
doi = "10.1177/009286150503900205",
language = "English",
volume = "39",
pages = "149--157",
journal = "Drug Information Journal",
issn = "0092-8615",
publisher = "Drug Information Association",
number = "2",

}

The expected toxicity rate at the maximum tolerated dose in bridging studies in Alzheimer's disease. / Kang, Seung Ho; Ahn, Chul.

In: Drug Information Journal, Vol. 39, No. 2, 01.01.2005, p. 149-157.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The expected toxicity rate at the maximum tolerated dose in bridging studies in Alzheimer's disease

AU - Kang, Seung Ho

AU - Ahn, Chul

PY - 2005/1/1

Y1 - 2005/1/1

N2 - A bridging study has been recommended to determine the maximum tolerated dose in Alzheimer's disease patients, because the maximum tolerated dose in the Alzheimer's disease patient population versus the normal population can vary greatly. Although bridging studies in Alzheimer's disease have often been conducted, it is surprising to note that very little is known about the statistical properties of the studies. For example, even how toxic the maximum tolerated dose is has not been examined. In addition, both the number of patients needed and the number of patients who will experience the toxicity cannot be predicted either. In this paper, we examine the exact statistical properties of a fixed-dose panel design which is frequently used in bridging studies in Alzheimer's disease. We introduce the formulas for the overall toxicity rate at the maximum tolerated dose, the expected number of patients who will experience the overall toxicity, and the expected number of patients in the bridging studies in Alzheimer's disease. The exact statistical properties of bridging studies depend on the unknown dose-toxicity curve. In this paper, we assume the logistic and the hyperbolic tangent functions as the true dose-toxicity curves, because the two families of functions seem to include most practical dose-toxicity curves. Based on the assumptions we investigate extensively the exact statistical properties of the bridging studies in Alzheimer clinical trials. The investigation shows that the expected toxicity rate at the maximum tolerated dose ranges from 18% to 30%. All rights reserved.

AB - A bridging study has been recommended to determine the maximum tolerated dose in Alzheimer's disease patients, because the maximum tolerated dose in the Alzheimer's disease patient population versus the normal population can vary greatly. Although bridging studies in Alzheimer's disease have often been conducted, it is surprising to note that very little is known about the statistical properties of the studies. For example, even how toxic the maximum tolerated dose is has not been examined. In addition, both the number of patients needed and the number of patients who will experience the toxicity cannot be predicted either. In this paper, we examine the exact statistical properties of a fixed-dose panel design which is frequently used in bridging studies in Alzheimer's disease. We introduce the formulas for the overall toxicity rate at the maximum tolerated dose, the expected number of patients who will experience the overall toxicity, and the expected number of patients in the bridging studies in Alzheimer's disease. The exact statistical properties of bridging studies depend on the unknown dose-toxicity curve. In this paper, we assume the logistic and the hyperbolic tangent functions as the true dose-toxicity curves, because the two families of functions seem to include most practical dose-toxicity curves. Based on the assumptions we investigate extensively the exact statistical properties of the bridging studies in Alzheimer clinical trials. The investigation shows that the expected toxicity rate at the maximum tolerated dose ranges from 18% to 30%. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=18444384262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444384262&partnerID=8YFLogxK

U2 - 10.1177/009286150503900205

DO - 10.1177/009286150503900205

M3 - Article

VL - 39

SP - 149

EP - 157

JO - Drug Information Journal

JF - Drug Information Journal

SN - 0092-8615

IS - 2

ER -